|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest earning deposits with other banks | ||||||||||||||||||||
| Investment securities, available-for-sale, at fair value | ||||||||||||||||||||
| Investment securities, held-to-maturity, at amortized cost | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Loans held for sale | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Total loans receivable, net | ||||||||||||||||||||
| CCBX credit enhancement asset | ||||||||||||||||||||
| CCBX credit enhancement asset, net | ||||||||||||||||||||
| CCBX receivable | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Lease right-of-use assets | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Bank-owned life insurance, net | ||||||||||||||||||||
| Deferred tax asset, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Principal amount $45,000 (less unamortized debt issuance costs of $482 and $557) at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Principal amount $3,609 (less unamortized debt issuance costs of $15 and $16 at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Deferred compensation | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Operating lease liabilities | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| CCBX payable | ||||||||||||||||||||
| Deferred tax liability, net | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| SHAREHOLDERS’ EQUITY | ||||||||||||||||||||
| Authorized: 25,000,000 shares at June 30, 2026 and December 31, 2025; issued and outstanding: zero shares at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Authorized: 300,000,000 shares at June 30, 2026 and December 31, 2025; 15,280,689 shares at June 30, 2026 issued and outstanding and 15,140,192 shares at December 31, 2025 issued and outstanding | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss, net of tax | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
